EP2478909A2 — Pharmaceutical compositions comprising bisphosphonate derivatives and high-dose cholecalciferol
Assigned to Hanlim Pharmaceutical Co Ltd · Expires 2012-07-25 · 14y expired
What this patent protects
The present invention provides a pharmaceutical composition for preventing or treating osteoporosis to be administered once a month, the pharmaceutical composition comprising a bisphosphonate derivative, such as risedronic acid (or its salt) or ibandronic acid (or its salt), and …
USPTO Abstract
The present invention provides a pharmaceutical composition for preventing or treating osteoporosis to be administered once a month, the pharmaceutical composition comprising a bisphosphonate derivative, such as risedronic acid (or its salt) or ibandronic acid (or its salt), and cholecalciferol in a high-dose. The present invention also provides a pharmaceutical composition for preventing or treating osteoporosis to be administered once a month, the pharmaceutical composition comprising: (a) cholecalciferol-containing granules obtained by adsorbing on microcrystalline cellulose a solution prepared by dissolving (i) cholecalciferol in an amount corresponding to 24,000 to 50,000 IU; (ii) one or more selected from tocopheryl acetate, butylhydroxytoluene, and butylhydroxyanisol as a first stabilizing agent; and (iii) a binder in ethanol or an aqueous solution of ethanol, (b) mannitol as a second stabilizing agent, and (c) risedronic acid or its salt or ibandronic acid or its salt.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.